FDA Clears Next-Gen Contrast Management System for the Cath Lab
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
FDA Clears Acist Pro Diagnostic System
May 18, 2026—Acist Medical Systems, Inc., a Bracco company, announced FDA clearance and the United States launch of the Acist Pro diagnostic system, which is a next-generation variable-rate contrast management solution for image-guided cardiovascular procedures. The company stated that the system is designed for precision, safety, and efficiency. According to Acist, the new system is the evolution of its Acist CVi automated contrast delivery tec…
FDA Clears New Contrast Management System for Cardiovascular Procedures
The ACIST Pro Diagnostic System provides automated contrast delivery to improve efficiency and safety in cardiac catheterization labs. ACIST Medical Systems, a Bracco company, announced US Food and Drug Administration clearance and the US launch of the ACIST Pro Diagnostic System. The technology is a variable-rate contrast management solution designed for use in image-guided cardiovascular procedures. The system is the next iteration of the comp…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
